Unaltered hippocampal dihydropyridine and omega-conotoxin GVIA binding sites after repeated electroconvulsive shock in rats.
Dooley
D J
DJ
Department of Neuroscience, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48106-1047.
D000818:Animals; D001143:Arousal / Q000502:physiology*; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D015220:Calcium Channels / Q000502:physiology*; D004082:Dihydroalprenolol / Q000493:pharmacokinetics; D004095:Dihydropyridines / Q000493:pharmacokinetics*; D004597:Electroshock; D006624:Hippocampus / Q000502:physiology*; D008297:Male; D010456:Peptides, Cyclic / Q000493:pharmacokinetics*; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011943:Receptors, Adrenergic, beta / Q000502:physiology; D017981:Receptors, Neurotransmitter / Q000502:physiology*; D020866:omega-Conotoxin GVIA
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D004095:Dihydropyridines; D010456:Peptides, Cyclic; D011943:Receptors, Adrenergic, beta; D017981:Receptors, Neurotransmitter; C028413:dihydroalprenolol receptor; C053157:omega-conotoxin receptor; D004082:Dihydroalprenolol; C038806:1,4-dihydropyridine; D020866:omega-Conotoxin GVIA